Gilead Sciences is a finished-dose manufacturer based in United Arab Emirates. It holds 3 active US drug master files across a filed portfolio of 3 molecules. Its filings concentrate with AEMPS (ES), URPL (PL) and Health Canada. Its GMP standing is certified by EMA, ZLG (DE) and COFEPRIS (MX), among 13 authorities. Its most recent recorded inspection, by US FDA, closed on 18 February 2026 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| CAIRO, United Arab Emirates | Not on file |
| Clearwater, United Arab Emirates | Not on file |
| Tampa, United Arab Emirates | Not on file |
| Rochester, United Arab Emirates | Not on file |
| Waterford, United Arab Emirates | Not on file |
| Monza Brianza, United Arab Emirates | Not on file |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Cobicistat | US FDA | 1 |
| Elvitegravir | US FDA | 1 |
| Penicillamine | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| AEMPS (ES) | 476 | None |
| URPL (PL) | 432 | None |
| Health Canada | 384 | None |
| EDA (EG) | 319 | 1 |
| EMA | 270 | 12 |
| US FDA | 205 | 5 |
| ZLG (DE) | None | 10 |
| COFEPRIS (MX) | None | 8 |
| ANVISA (Brazil) | None | 5 |
| HSA (SG) | None | 4 |
| MHRA (UK) | None | 4 |
| ANSM (FR) | None | 3 |
| MFDS (Korea) | None | 2 |
| INVIMA (CO) | None | 2 |
| NAFDAC (NG) | None | 1 |
| UZPHARM (UZ) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2020 | $7.4B | Not reported | Not reported |
| 2019 | $5.9B | Not reported | Not reported |
| 2018 | $5.8B | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Gilead Sciences comes back tiered against every other supplier able to file there.
Start for free